MarginsXMarginsX
Home › Markets › Health Care › SCNX

Scienture Holdings Inc. (SCNX)

SCNX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.99
+3.10% on the day
Market cap
$4.9M
Nano cap
Revenue · 2025
$432K
+215.9% on 2024
Net income · 2025
-$41.5M
-9618.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1382574/000149315226013475/0001493152-26-013475-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSCNX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001382574

Financials · 2025

LineValue
Revenue$432K
Net income-$41.5M
Operating income-$42.6M
Net margin-9618.0%
Operating margin-9867.9%
Revenue growth+215.9%
Cash$6.7M
Total assets$84.2M
P/E (computed)Net income was not positive
P/S (computed)11.4×

Warning signs

Cash runway
6.8 months
$8.2M cash at June 30, 2026
Share count, 1 year
+154.6%
2025-08-12 to 2026-08-13 · +3192.6% over 3 years
Going-concern doubt
Yes
10-Q filed August 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The negative effect on our business and our ability to raise capital that is created by the fact that there is a substantial doubt about our ability to continue as a going concern;"
10-Q 2026-08-13
Cash and burn$8.2M cash; operating cash flow -$3.6M a quarter.Report 2026-06-30
Shares outstanding1,642,566 (2026-08-13); 16,131,180 a year earlier; 1,247,169 three years earlier.Cover page 2026-08-13
Reverse splits, 3 years1; latest 1-for-25 on 2026-10-05Source 2026-10-05
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-10-19
AuditorCM3 Advisory, San Diego, California, United StatesPCAOB Form AP 2026-05-04
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$344K-$2.8M-$3.1M$8.2M$1.1M$821K10-Q 2026-08-13
Q1 2026
2026-03-31
$56K-$3.4M-$2.9M$3.5MNo debt tags$478K10-Q 2026-05-15
Q4 2025
2025-12-31
-$169K-$28.1M-$5.2M$6.7MNo debt tags$432K10-K 2026-03-30
Q3 2025
2025-09-30
$590K-$3.6M-$3.2M$356K$2.0M$653K10-Q 2025-11-12
Q2 2025
2025-06-30
$0-$6.7M-$2.0M$15K$3.6M$128K10-Q 2026-08-13
Q1 2025
2025-03-31
$10K-$3.1M-$3.0M$2.0M$3.1M$147K10-Q 2026-05-15
Q4 2024
2024-12-31
$53K-$7.2M-$2.9M$308K$2.9M$137K10-K 2026-03-30
Q3 2024
2024-09-30
$65K-$3.2M-$5.4M$579KNo debt tagsNeeds four quarters10-Q 2025-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week-7.2%
1 month-10.5%
3 months-75.1%
Year to date-77.3%
1 year-82.7%
From 52-week high-82.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PULMPulmatrix Inc.$1.33+2.31%$4.9M
CVKDCadrenal Therapeutics Inc.$1.40-7.28%$5.0M
PCSAProcessa Pharmaceuticals Inc.$1.72-7.53%$4.8M
CNSPCNS Pharmaceuticals Inc.$3.48+20.42%$5.1M
CANFCan-Fite Biopharma Ltd$1.56+9.86%$4.7M
SKYESkye Bioscience Inc.$1.06-2.29%$4.7M
JAGXJaguar Health Inc.$0.3864-7.74%$5.2M
NCNANuCana plc American Depositary Share$0.8631-7.46%$4.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier